Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E

The Journal of Clinical Investigation
T EbaraN S Shachter

Abstract

The mechanism of apolipoprotein (apo) CIII-induced hypertriglyceridemia remains uncertain. We crossed apoCIII transgenic and apoE gene knockout (apoE0) mice, and observed severe hypertriglyceridemia with plasma triglyceride levels of 4,521+/-6, 394 mg/dl vs. 423+/-106 mg/dl in apoE0 mice, P < 0.00001 for log(triglycerides [TG]). Cholesterols were 1,181+/-487 mg/dl vs. 658+/-151 mg/dl, P < 0.0001. Lipoprotein fractionation showed a marked increase in triglyceride-enriched chylomicrons+VLDL. This increase was limited to the lowest density (chylomicrons and Sf 100-400) subfractions. Intermediate density lipoproteins (IDL)+LDL increased moderately, and HDL decreased. There was no significant increase in triglyceride production in apoCIII transgenic/apoE0 mice. The clearance of VLDL triglycerides, however, was significantly decreased. Lipoprotein lipase in postheparin plasma was elevated, but activation studies suggested LPL inhibition by both apoCIII transgenic and apoCIII transgenic/apoE0 plasma. ApoCIII overexpression also produced a marked decrease in VLDL glycosaminoglycan binding which was independent of apoE. The predominant mechanism of apoCIII-induced hypertriglyceridemia appears to be decreased lipolysis at the cell surfac...Continue Reading

References

Nov 11, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J R PatschW Patsch
May 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·P H GrootL Havekes
Dec 1, 1990·Atherosclerosis·H S SimpsonJ Shepherd
May 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·T Sane, E A Nikkilä
Feb 1, 1985·The Journal of Clinical Investigation·C S WangP Alaupovic
Jan 31, 1972·Biochemical and Biophysical Research Communications·W V Brown, M L Baginsky
Jul 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·V ClaveyJ C Fruchart
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·A S PlumpJ L Breslow
Mar 1, 1994·Atherosclerosis·F KarpeA Hamsten
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M DammermanJ L Breslow
Apr 1, 1994·The Journal of Clinical Investigation·N S ShachterJ L Breslow
Aug 1, 1996·The Journal of Clinical Investigation·N S ShachterJ D Smith
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON

❮ Previous
Next ❯

Citations

Dec 21, 2000·Current Atherosclerosis Reports·W PatschJ R Patsch
Dec 21, 2000·Current Atherosclerosis Reports·J C FruchartP Duriez
Jul 11, 2002·The American Journal of Cardiology·Frank M SacksLemuel A Moye
Aug 2, 2003·Gastroenterology·Thierry ClaudelBart Staels
Oct 18, 2003·Metabolism: Clinical and Experimental·Toshihiro TakahashiMitsuru Adachi
Jan 14, 2003·Seminars in Cell & Developmental Biology·Peter Marschang, Joachim Herz
Sep 17, 2008·Proceedings of the National Academy of Sciences of the United States of America·Maxwell A RubyRonald M Krauss
Jul 6, 2000·Current Opinion in Lipidology·I J GoldbergE P Lutz
May 16, 2001·Current Opinion in Lipidology·N S Shachter
May 29, 2004·Current Opinion in Lipidology·Ko Willems van DijkLouis M Havekes
Mar 16, 2005·Current Opinion in Lipidology·Chao-Qiang LaiJose M Ordovas
Jun 17, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Mirjana PavlicGary F Lewis
Aug 2, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Zhouji ChenBrian N Finck
Nov 17, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Carlos O MendivilFrank M Sacks
Sep 4, 1999·Clinical Chemistry and Laboratory Medicine : CCLM·B NollA Steinmetz
Oct 11, 2007·Pharmacogenomics·George V Z Dedoussis
Feb 6, 2016·Cardiovascular Drugs and Therapy·Yanhong GuoY Eugene Chen
Feb 5, 2002·Expert Opinion on Pharmacotherapy·P Duriez
Jul 12, 2016·The Journal of Clinical Investigation·Philip L S M GordtsJeffrey D Esko
Sep 8, 2015·Journal of Clinical Lipidology·Piers R BlackettCatherine J McNeal
Dec 4, 2014·The New England Journal of Medicine·Daniel GaudetJoseph L Witztum
Sep 11, 2016·Current Atherosclerosis Reports·Marja-Riitta Taskinen, Jan Borén
Feb 24, 2006·Journal of Lipid Research·Jean-François MaugerBenoît Lamarche
Feb 25, 2006·Journal of Lipid Research·Hafid MezdourNobuyo Maeda

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.